Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.57 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681706 | 0.80 | IKBKB (0.67) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL19206637 | 0.79 | PARP1 (0.56) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL4093060 | 0.76 | JAK2 (0.64) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL10051836 | 0.76 | IKBKB (0.68) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL7053472 | 0.75 | IKBKB (0.66) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL1929743 | 0.74 | CHEK1 (0.50) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL4088216 | 0.74 | IKBKB (0.74) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL1385889 | 0.74 | JAK2 (1.00) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL4086973 | 0.74 | JAK2 (0.72) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL27585211 | 0.73 | PARP1 (0.53) | IKBKBMEN1KMT2ATDP1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | claimed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | claimed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | claimed |
| CN-1538968-A | Novel compounds | — | 2004-10-20 | — | — | CN | claimed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | claimed |
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| CN-1538968-A | Novel compounds | — | 2004-10-20 | — | — | CN | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | IKBKB 2823/4885JAK2 378/4885JAK3 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.